Diabetes - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols LMNA and DEFB127	Name 1 lamin A/C	Name2 defensin beta 127	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 Beta defensins Defensins	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel Novel	Symbols BCR and BLK	Name 1 BCR activator of RhoGEF and GTPase	Name2 BLK proto-oncogene, Src family tyrosine kinase	Pathway 1 Signaling by cytosolic FGFR1 fusion mutants Signaling by FGFR1 in disease RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RAC3 GTPase cycle	Pathway 2 RUNX1 regulates transcription of genes involved in BCR signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Drugs 1 Imatinib Dasatinib Bosutinib Ponatinib	Drugs 2 Fostamatinib Zanubrutinib	Diseases 1 Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Chronic myeloid leukemia (CML)	Diseases 2 Maturity onset diabetes of the young (MODY)
Novel Novel	Symbols BCL2 and CPT1A	Name 1 BCL2 apoptosis regulator	Name2 carnitine palmitoyltransferase 1A	Pathway 1 Activation of BAD and translocation to mitochondria BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Interleukin-4 and Interleukin-13 signaling The NLRP1 inflammasome Estrogen-dependent gene expression Estrogen-dependent nuclear events downstream of ESR-membrane signaling NFE2L2 regulating tumorigenic genes Regulation of MITF-M-dependent genes involved in apoptosis	Pathway 2 PPARA activates gene expression Carnitine shuttle RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression	Drugs 1 Ibuprofen Paclitaxel Docetaxel Rasagiline AN-9 Paclitaxel docosahexaenoic acid Apoptone Eribulin Dexibuprofen Venetoclax Obatoclax Navitoclax Terpinen-4-ol Oleandrin	Drugs 2 Levocarnitine Glyburide Perhexiline	Diseases 1 Cervical cancer Kaposi's sarcoma Chronic lymphocytic leukemia (CLL) Gastric cancer Nasopharyngeal cancer Choriocarcinoma Small cell lung cancer	Diseases 2 Disorders of fatty-acid oxidation, including: Medium-chain (MC) acyl-CoA dehydrogenase (AD) deficiency (MCADD); Short-chain AD deficiency (SCADD) ; Short-branched-chain AD deficiency (SBCADD) ; Very long-chain AD deficiency (VLCADD) ; Long-chain 3-hydroxyacyl CoA dehydrogenase deficiency (LCHADD) ; Trifunctional protein deficiency (TFP); Carnitine palmitoyltransferase deficiency (CPT); Carnitine-acylcarnitine translocase deficiency (CACT); Systemic primary carnitine deficiency (CDSP)
Novel Novel	Symbols XRCC6 and PLGRKT	Name 1 X-ray repair cross complementing 6	Name2 plasminogen receptor with a C-terminal lysine	Pathway 1 2-LTR circle formation Cytosolic sensors of pathogen-associated DNA IRF3-mediated induction of type I IFN Nonhomologous End-Joining (NHEJ) Neutrophil degranulation	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols XRCC6 and PDX1	Name 1 X-ray repair cross complementing 6	Name2 pancreatic and duodenal homeobox 1	Pathway 1 2-LTR circle formation Cytosolic sensors of pathogen-associated DNA IRF3-mediated induction of type I IFN Nonhomologous End-Joining (NHEJ) Neutrophil degranulation	Pathway 2 Regulation of gene expression in beta cells Regulation of gene expression in early pancreatic precursor cells Developmental Lineage of Pancreatic Acinar Cells Developmental Lineage of Pancreatic Ductal Cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Permanent neonatal diabetes mellitus (PNDM) Pancreatic agenesis Maturity onset diabetes of the young (MODY)
Novel Novel	Symbols MITF and TFEB	Name 1 melanocyte inducing transcription factor	Name2 transcription factor EB	Pathway 1 SUMOylation of transcription factors Transcriptional and post-translational regulation of MITF-M expression and activity	Pathway 2 Transcriptional and post-translational regulation of MITF-M expression and activity Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes	Drugs 1	Drugs 2	Diseases 1 Malignant melanoma Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA) Waardenburg syndrome (WS)	Diseases 2
Novel Novel	Symbols MC4R and ATRNL1	Name 1 melanocortin 4 receptor	Name2 attractin like 1	Pathway 1 Peptide ligand-binding receptors G alpha (s) signalling events Transcriptional and post-translational regulation of MITF-M expression and activity	Pathway 2	Drugs 1 Bremelanotide Setmelanotide	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols MBD1 and HUNK	Name 1 methyl-CpG binding domain protein 1	Name2 hormonally up-regulated Neu-associated kinase	Pathway 1 SUMOylation of transcription cofactors	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols MBD1 and OASL	Name 1 methyl-CpG binding domain protein 1	Name2 2'-5'-oligoadenylate synthetase like	Pathway 1 SUMOylation of transcription cofactors	Pathway 2 Interferon gamma signaling OAS antiviral response Interferon alpha/beta signaling	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols MCM7 and CEP68	Name 1 minichromosome maintenance complex component 7	Name2 centrosomal protein 68	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FHL2 and IGFBP5	Name 1 four and a half LIM domains 2	Name2 insulin like growth factor binding protein 5	Pathway 1 PPARA activates gene expression	Pathway 2 Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FHL2 and BARX2	Name 1 four and a half LIM domains 2	Name2 BARX homeobox 2	Pathway 1 PPARA activates gene expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FHL2 and PHF21A	Name 1 four and a half LIM domains 2	Name2 PHD finger protein 21A	Pathway 1 PPARA activates gene expression	Pathway 2 HDACs deacetylate histones Potential therapeutics for SARS Factors involved in megakaryocyte development and platelet production	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FHL2 and A1CF	Name 1 four and a half LIM domains 2	Name2 APOBEC1 complementation factor	Pathway 1 PPARA activates gene expression	Pathway 2 mRNA Editing: C to U Conversion Formation of the Editosome	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FHL2 and ANKRD55	Name 1 four and a half LIM domains 2	Name2 ankyrin repeat domain 55	Pathway 1 PPARA activates gene expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FHL2 and GNG4	Name 1 four and a half LIM domains 2	Name2 G protein subunit gamma 4	Pathway 1 PPARA activates gene expression	Pathway 2 Activation of G protein gated Potassium channels Glucagon signaling in metabolic regulation G-protein activation Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Glucagon-like Peptide-1 (GLP1) regulates insulin secretion ADP signalling through P2Y purinoceptor 12 G beta:gamma signalling through PI3Kgamma Prostacyclin signalling through prostacyclin receptor Prostacyclin signalling through prostacyclin receptor Adrenaline,noradrenaline inhibits insulin secretion Adrenaline,noradrenaline inhibits insulin secretion Ca2+ pathway Ca2+ pathway G alpha (q) signalling events G alpha (12/13) signalling events G beta:gamma signalling through PLC beta G alpha (s) signalling events ADP signalling through P2Y purinoceptor 1 ADP signalling through P2Y purinoceptor 1 G alpha (i) signalling events G alpha (z) signalling events Glucagon-type ligand receptors Thromboxane signalling through TP receptor Vasopressin regulates renal water homeostasis via Aquaporins Thrombin signalling through proteinase activated receptors (PARs) Thrombin signalling through proteinase activated receptors (PARs) Presynaptic function of Kainate receptors Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding G beta:gamma signalling through BTK G beta:gamma signalling through CDC42 Extra-nuclear estrogen signaling GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FHL2 and SLC34A1	Name 1 four and a half LIM domains 2	Name2 solute carrier family 34 member 1	Pathway 1 PPARA activates gene expression	Pathway 2 Type II Na+/Pi cotransporters Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1) Surfactant metabolism	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Nephrolithiasis/osteoporosis, hypophosphatemic
Novel Novel	Symbols CCN3 and DLL1	Name 1 cellular communication network factor 3	Name2 delta like canonical Notch ligand 1	Pathway 1	Pathway 2 Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Constitutive Signaling by NOTCH1 HD Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants NOTCH2 Activation and Transmission of Signal to the Nucleus NOTCH2 Activation and Transmission of Signal to the Nucleus NOTCH3 Activation and Transmission of Signal to the Nucleus NOTCH3 Activation and Transmission of Signal to the Nucleus MECP2 regulates transcription of neuronal ligands Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin Formation of paraxial mesoderm Somitogenesis Nephron development	Drugs 1 Insulin human	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols AFDN and NRXN1	Name 1 afadin, adherens junction formation factor	Name2 neurexin 1	Pathway 1	Pathway 2 Neurexins and neuroligins Neurexins and neuroligins Non-integrin membrane-ECM interactions Neurexins and neuroligins Neurexins and neuroligins	Drugs 1 (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one	Drugs 2 Calcium citrate Calcium Phosphate Calcium phosphate dihydrate	Diseases 1	Diseases 2 Pitt-Hopkins syndrome, including: Pitt-Hopkins syndrome; Pitt-Hopkins-like syndrome
Novel Novel	Symbols AFDN and NRXN3	Name 1 afadin, adherens junction formation factor	Name2 neurexin 3	Pathway 1	Pathway 2 Neurexins and neuroligins Neurexins and neuroligins Neurexins and neuroligins Neurexins and neuroligins	Drugs 1 (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols LMNA and DEFB127	Name 1 lamin A/C	Name2 defensin beta 127	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 Beta defensins Defensins	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel	Symbols BCR and BLK	Name 1 BCR activator of RhoGEF and GTPase	Name2 BLK proto-oncogene, Src family tyrosine kinase	Pathway 1 Signaling by cytosolic FGFR1 fusion mutants Signaling by FGFR1 in disease RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RAC3 GTPase cycle	Pathway 2 RUNX1 regulates transcription of genes involved in BCR signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Drugs 1 Imatinib Dasatinib Bosutinib Ponatinib	Drugs 2 Fostamatinib Zanubrutinib	Diseases 1 Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Chronic myeloid leukemia (CML)	Diseases 2 Maturity onset diabetes of the young (MODY)
Novel	Symbols BCL2 and CPT1A	Name 1 BCL2 apoptosis regulator	Name2 carnitine palmitoyltransferase 1A	Pathway 1 Activation of BAD and translocation to mitochondria BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Interleukin-4 and Interleukin-13 signaling The NLRP1 inflammasome Estrogen-dependent gene expression Estrogen-dependent nuclear events downstream of ESR-membrane signaling NFE2L2 regulating tumorigenic genes Regulation of MITF-M-dependent genes involved in apoptosis	Pathway 2 PPARA activates gene expression Carnitine shuttle RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression	Drugs 1 Ibuprofen Paclitaxel Docetaxel Rasagiline AN-9 Paclitaxel docosahexaenoic acid Apoptone Eribulin Dexibuprofen Venetoclax Obatoclax Navitoclax Terpinen-4-ol Oleandrin	Drugs 2 Levocarnitine Glyburide Perhexiline	Diseases 1 Cervical cancer Kaposi's sarcoma Chronic lymphocytic leukemia (CLL) Gastric cancer Nasopharyngeal cancer Choriocarcinoma Small cell lung cancer	Diseases 2 Disorders of fatty-acid oxidation, including: Medium-chain (MC) acyl-CoA dehydrogenase (AD) deficiency (MCADD); Short-chain AD deficiency (SCADD) ; Short-branched-chain AD deficiency (SBCADD) ; Very long-chain AD deficiency (VLCADD) ; Long-chain 3-hydroxyacyl CoA dehydrogenase deficiency (LCHADD) ; Trifunctional protein deficiency (TFP); Carnitine palmitoyltransferase deficiency (CPT); Carnitine-acylcarnitine translocase deficiency (CACT); Systemic primary carnitine deficiency (CDSP)
Novel	Symbols XRCC6 and PLGRKT	Name 1 X-ray repair cross complementing 6	Name2 plasminogen receptor with a C-terminal lysine	Pathway 1 2-LTR circle formation Cytosolic sensors of pathogen-associated DNA IRF3-mediated induction of type I IFN Nonhomologous End-Joining (NHEJ) Neutrophil degranulation	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols XRCC6 and PDX1	Name 1 X-ray repair cross complementing 6	Name2 pancreatic and duodenal homeobox 1	Pathway 1 2-LTR circle formation Cytosolic sensors of pathogen-associated DNA IRF3-mediated induction of type I IFN Nonhomologous End-Joining (NHEJ) Neutrophil degranulation	Pathway 2 Regulation of gene expression in beta cells Regulation of gene expression in early pancreatic precursor cells Developmental Lineage of Pancreatic Acinar Cells Developmental Lineage of Pancreatic Ductal Cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Permanent neonatal diabetes mellitus (PNDM) Pancreatic agenesis Maturity onset diabetes of the young (MODY)
Novel	Symbols MITF and TFEB	Name 1 melanocyte inducing transcription factor	Name2 transcription factor EB	Pathway 1 SUMOylation of transcription factors Transcriptional and post-translational regulation of MITF-M expression and activity	Pathway 2 Transcriptional and post-translational regulation of MITF-M expression and activity Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes	Drugs 1	Drugs 2	Diseases 1 Malignant melanoma Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA) Waardenburg syndrome (WS)	Diseases 2
Novel	Symbols MC4R and ATRNL1	Name 1 melanocortin 4 receptor	Name2 attractin like 1	Pathway 1 Peptide ligand-binding receptors G alpha (s) signalling events Transcriptional and post-translational regulation of MITF-M expression and activity	Pathway 2	Drugs 1 Bremelanotide Setmelanotide	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols MBD1 and HUNK	Name 1 methyl-CpG binding domain protein 1	Name2 hormonally up-regulated Neu-associated kinase	Pathway 1 SUMOylation of transcription cofactors	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols MBD1 and OASL	Name 1 methyl-CpG binding domain protein 1	Name2 2'-5'-oligoadenylate synthetase like	Pathway 1 SUMOylation of transcription cofactors	Pathway 2 Interferon gamma signaling OAS antiviral response Interferon alpha/beta signaling	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols MCM7 and CEP68	Name 1 minichromosome maintenance complex component 7	Name2 centrosomal protein 68	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FHL2 and IGFBP5	Name 1 four and a half LIM domains 2	Name2 insulin like growth factor binding protein 5	Pathway 1 PPARA activates gene expression	Pathway 2 Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FHL2 and BARX2	Name 1 four and a half LIM domains 2	Name2 BARX homeobox 2	Pathway 1 PPARA activates gene expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FHL2 and PHF21A	Name 1 four and a half LIM domains 2	Name2 PHD finger protein 21A	Pathway 1 PPARA activates gene expression	Pathway 2 HDACs deacetylate histones Potential therapeutics for SARS Factors involved in megakaryocyte development and platelet production	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FHL2 and A1CF	Name 1 four and a half LIM domains 2	Name2 APOBEC1 complementation factor	Pathway 1 PPARA activates gene expression	Pathway 2 mRNA Editing: C to U Conversion Formation of the Editosome	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FHL2 and ANKRD55	Name 1 four and a half LIM domains 2	Name2 ankyrin repeat domain 55	Pathway 1 PPARA activates gene expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FHL2 and GNG4	Name 1 four and a half LIM domains 2	Name2 G protein subunit gamma 4	Pathway 1 PPARA activates gene expression	Pathway 2 Activation of G protein gated Potassium channels Glucagon signaling in metabolic regulation G-protein activation Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Glucagon-like Peptide-1 (GLP1) regulates insulin secretion ADP signalling through P2Y purinoceptor 12 G beta:gamma signalling through PI3Kgamma Prostacyclin signalling through prostacyclin receptor Prostacyclin signalling through prostacyclin receptor Adrenaline,noradrenaline inhibits insulin secretion Adrenaline,noradrenaline inhibits insulin secretion Ca2+ pathway Ca2+ pathway G alpha (q) signalling events G alpha (12/13) signalling events G beta:gamma signalling through PLC beta G alpha (s) signalling events ADP signalling through P2Y purinoceptor 1 ADP signalling through P2Y purinoceptor 1 G alpha (i) signalling events G alpha (z) signalling events Glucagon-type ligand receptors Thromboxane signalling through TP receptor Vasopressin regulates renal water homeostasis via Aquaporins Thrombin signalling through proteinase activated receptors (PARs) Thrombin signalling through proteinase activated receptors (PARs) Presynaptic function of Kainate receptors Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding G beta:gamma signalling through BTK G beta:gamma signalling through CDC42 Extra-nuclear estrogen signaling GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FHL2 and SLC34A1	Name 1 four and a half LIM domains 2	Name2 solute carrier family 34 member 1	Pathway 1 PPARA activates gene expression	Pathway 2 Type II Na+/Pi cotransporters Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1) Surfactant metabolism	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Nephrolithiasis/osteoporosis, hypophosphatemic
Novel	Symbols CCN3 and DLL1	Name 1 cellular communication network factor 3	Name2 delta like canonical Notch ligand 1	Pathway 1	Pathway 2 Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Constitutive Signaling by NOTCH1 HD Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants NOTCH2 Activation and Transmission of Signal to the Nucleus NOTCH2 Activation and Transmission of Signal to the Nucleus NOTCH3 Activation and Transmission of Signal to the Nucleus NOTCH3 Activation and Transmission of Signal to the Nucleus MECP2 regulates transcription of neuronal ligands Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin Formation of paraxial mesoderm Somitogenesis Nephron development	Drugs 1 Insulin human	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols AFDN and NRXN1	Name 1 afadin, adherens junction formation factor	Name2 neurexin 1	Pathway 1	Pathway 2 Neurexins and neuroligins Neurexins and neuroligins Non-integrin membrane-ECM interactions Neurexins and neuroligins Neurexins and neuroligins	Drugs 1 (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one	Drugs 2 Calcium citrate Calcium Phosphate Calcium phosphate dihydrate	Diseases 1	Diseases 2 Pitt-Hopkins syndrome, including: Pitt-Hopkins syndrome; Pitt-Hopkins-like syndrome
Novel	Symbols AFDN and NRXN3	Name 1 afadin, adherens junction formation factor	Name2 neurexin 3	Pathway 1	Pathway 2 Neurexins and neuroligins Neurexins and neuroligins Neurexins and neuroligins Neurexins and neuroligins	Drugs 1 (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one	Drugs 2	Diseases 1	Diseases 2

Page 26 out of 58 pages

Search Results : Diabetes